Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy

NCT04876534 is registered in ClinicalTrials.gov with Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico as lead sponsor.

NCT NCT04876534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04876534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Observer-blind, Controlled Study of the Anti-IL-6 Receptor Antibody Tocilizumab (TCZ) or Methylprednisolone (MP) Treatment in Patients With Active Moderate-severe Graves' Orbitopathy
Lead sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase
Phase 2
Overall status
Unknown status
Start date
December 18, 2019
Completion date
December 18, 2023
Enrollment
64 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

graves ophthalmopathy